High performance liquid chromatography of Carbon-11 labeled thymidine and its major catabolites for clinical PET studies

Peter S. Conti; John Hilton; Dean F. Wong; Mian M. Alauddin; Robert F. Dannals; Hayden T. Ravert; Alan A. Wilson; James H. Anderson

doi:10.1016/0969-8051(94)90176-7

High performance liquid chromatography of Carbon-11 labeled thymidine and its major catabolites for clinical PET studies

Peter S. Conti, John Hilton, Dean F. Wong, Mian M. Alauddin, Robert F. Dannals, Hayden T. Ravert, Alan A. Wilson, James H. Anderson

School of Medicine

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

The identity and pharmacology of the rapidly formed radiolabeled metabolites formed following i.v. injection of C-11 thymidine (TdR) labeled in the 5-methyl-position are being studied in animal models and patients with cancer. A high performance liquid chromatographic (HPLC) procedure has been developed for the separation of these metabolites including thymine, dihydrothymine, β-ureidoisobutyric acid, and β-aminoisobutyric acid from plasma and tissue extracts. Information obtained regarding the pharmacokinetics of the metabolites are being used to generate mathematical models for C-11 TdR incorporation rates into DNA.

Original language	English (US)
Pages (from-to)	1045-1051
Number of pages	7
Journal	Nuclear Medicine and Biology
Volume	21
Issue number	8
DOIs	https://doi.org/10.1016/0969-8051(94)90176-7
State	Published - Nov 1994

ASJC Scopus subject areas

Molecular Medicine
Radiology Nuclear Medicine and imaging
Cancer Research

Access to Document

10.1016/0969-8051(94)90176-7

Cite this

@article{1670c44f880d482291ec7572fb45746c,

title = "High performance liquid chromatography of Carbon-11 labeled thymidine and its major catabolites for clinical PET studies",

abstract = "The identity and pharmacology of the rapidly formed radiolabeled metabolites formed following i.v. injection of C-11 thymidine (TdR) labeled in the 5-methyl-position are being studied in animal models and patients with cancer. A high performance liquid chromatographic (HPLC) procedure has been developed for the separation of these metabolites including thymine, dihydrothymine, β-ureidoisobutyric acid, and β-aminoisobutyric acid from plasma and tissue extracts. Information obtained regarding the pharmacokinetics of the metabolites are being used to generate mathematical models for C-11 TdR incorporation rates into DNA.",

author = "Conti, {Peter S.} and John Hilton and Wong, {Dean F.} and Alauddin, {Mian M.} and Dannals, {Robert F.} and Ravert, {Hayden T.} and Wilson, {Alan A.} and Anderson, {James H.}",

note = "Funding Information: Acknowledgements-This work was supported in part by NIH grants CA 37870-08a nd CA 54112-01S. pecial thanks to Mr Robert Smoot for assistancein radiotracer production.",

year = "1994",

month = nov,

doi = "10.1016/0969-8051(94)90176-7",

language = "English (US)",

volume = "21",

pages = "1045--1051",

journal = "Nuclear Medicine and Biology",

issn = "0969-8051",

publisher = "Elsevier Inc.",

number = "8",

}

TY - JOUR

T1 - High performance liquid chromatography of Carbon-11 labeled thymidine and its major catabolites for clinical PET studies

AU - Conti, Peter S.

AU - Hilton, John

AU - Wong, Dean F.

AU - Alauddin, Mian M.

AU - Dannals, Robert F.

AU - Ravert, Hayden T.

AU - Wilson, Alan A.

AU - Anderson, James H.

N1 - Funding Information: Acknowledgements-This work was supported in part by NIH grants CA 37870-08a nd CA 54112-01S. pecial thanks to Mr Robert Smoot for assistancein radiotracer production.

PY - 1994/11

Y1 - 1994/11

N2 - The identity and pharmacology of the rapidly formed radiolabeled metabolites formed following i.v. injection of C-11 thymidine (TdR) labeled in the 5-methyl-position are being studied in animal models and patients with cancer. A high performance liquid chromatographic (HPLC) procedure has been developed for the separation of these metabolites including thymine, dihydrothymine, β-ureidoisobutyric acid, and β-aminoisobutyric acid from plasma and tissue extracts. Information obtained regarding the pharmacokinetics of the metabolites are being used to generate mathematical models for C-11 TdR incorporation rates into DNA.

AB - The identity and pharmacology of the rapidly formed radiolabeled metabolites formed following i.v. injection of C-11 thymidine (TdR) labeled in the 5-methyl-position are being studied in animal models and patients with cancer. A high performance liquid chromatographic (HPLC) procedure has been developed for the separation of these metabolites including thymine, dihydrothymine, β-ureidoisobutyric acid, and β-aminoisobutyric acid from plasma and tissue extracts. Information obtained regarding the pharmacokinetics of the metabolites are being used to generate mathematical models for C-11 TdR incorporation rates into DNA.

UR - http://www.scopus.com/inward/record.url?scp=0028618661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028618661&partnerID=8YFLogxK

U2 - 10.1016/0969-8051(94)90176-7

DO - 10.1016/0969-8051(94)90176-7

M3 - Article

C2 - 9234362

AN - SCOPUS:0028618661

SN - 0969-8051

VL - 21

SP - 1045

EP - 1051

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

IS - 8

ER -

High performance liquid chromatography of Carbon-11 labeled thymidine and its major catabolites for clinical PET studies

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this